Comparative Pharmacology
Head-to-head clinical analysis: FUSILEV versus VORAXAZE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FUSILEV versus VORAXAZE.
FUSILEV vs VORAXAZE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FUSILEV (levoleucovorin) is the pharmacologically active isomer of folinic acid. It bypasses dihydrofolate reductase inhibition by dihydrofolate reductase inhibitors (e.g., methotrexate), providing reduced folate that is used in DNA synthesis and repair. It also enhances the efficacy of fluorouracil by stabilizing the ternary complex of thymidylate synthase, thereby inhibiting DNA synthesis.
Glucarpidase is a recombinant bacterial enzyme that hydrolyzes the glutamate residue from methotrexate and its metabolites, converting them to nontoxic metabolites.
Leucovorin (Fusilev) 200 mg/m2 IV over 2 hours, followed by 5-fluorouracil bolus and infusion, repeated every 2 weeks in combination regimens for advanced colorectal cancer.
2000 units intravenously over 5 minutes as a single dose.
None Documented
None Documented
The terminal elimination half-life of the active metabolite, 5-methyltetrahydrofolate (5-MTHF), is approximately 6-8 hours in healthy adults; clinically, this supports twice-daily or daily dosing schedules.
Terminal elimination half-life is approximately 10 hours (range 6-16 hours) in patients with normal renal function. In patients with methotrexate-induced renal impairment, half-life may be prolonged up to 20-30 hours. Clinical context: the half-life determines the timing of repeat dosing or monitoring; a single dose typically reduces methotrexate levels by >97% within 15 minutes.
Primarily hepatic metabolism; renal excretion of metabolites accounts for approximately 40-60% of the dose; fecal excretion is negligible.
Voraxaze (glucarpidase) is a recombinant enzyme that rapidly cleaves circulating methotrexate into inactive metabolites (DAMPA and glutamate). It is not significantly renally or hepatically excreted; rather, it is a high-molecular-weight protein that is catabolized via proteolysis. The majority of the administered dose is metabolized and eliminated as smaller peptides and amino acids. Less than 1% is excreted unchanged in urine.
Category C
Category C
Antidote
Antidote